Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Progenics Pharmaceut (PGNX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 428,647
  • Shares Outstanding, K 70,270
  • Annual Sales, $ 69,430 K
  • Annual Income, $ 10,810 K
  • 36-Month Beta 3.42
  • Price/Sales 34.43
  • Price/Cash Flow 33.84
  • Price/Book 7.27

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.70 +10.00%
on 12/20/17
7.22 -13.16%
on 12/29/17
+0.57 (+10.00%)
since 12/19/17
3-Month
5.16 +21.51%
on 11/15/17
7.22 -13.16%
on 12/29/17
-0.23 (-3.54%)
since 10/19/17
52-Week
4.60 +36.30%
on 08/09/17
11.72 -46.50%
on 03/15/17
-2.63 (-29.55%)
since 01/19/17

Most Recent Stories

More News
Report: Developing Opportunities within Aduro Biotech, Progenics Pharmaceuticals, Gevo, OSI, Senseonics, and Donnelley Financial Solutions -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aduro Biotech, Inc. (NASDAQ:ADRO),...

SENS : 2.96 (-0.67%)
PGNX : 6.27 (+2.79%)
GEVO : 0.60 (+1.69%)
DFIN : 21.11 (+1.10%)
OSIS : 68.53 (+0.54%)
ADRO : 7.30 (+5.80%)
Goldman Sachs and Hess slide while PepsiCo and TiVo rise

NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday:

ADTN : 16.40 (-1.65%)
PGNX : 6.27 (+2.79%)
BCEI : 27.87 (-0.46%)
PEP : 120.17 (+0.94%)
ATRA : 29.50 (+7.27%)
Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for AZEDRA(R) (iobenguane I 131) in Pheochromocytoma and Paraganglioma

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that the U.S. Food and...

PGNX : 6.27 (+2.79%)
Look for Shares of Progenics Pharm to Potentially Rebound after Yesterday's 1.02% Sell Off

Progenics Pharm (NASDAQ:PGNX) traded in a range yesterday that spanned from a low of $5.77 to a high of $5.96. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $5.85...

PGNX : 6.27 (+2.79%)
Technical Snapshots for These Biotech Stocks -- Kura Oncology, Progenics Pharma, Regeneron Pharma, and Seattle Genetics

If you want a Stock Review on KURA, PGNX, REGN, or SGEN then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. For today, DailyStockTracker.com scans Kura...

PGNX : 6.27 (+2.79%)
KURA : 17.80 (+5.64%)
SGEN : 53.48 (+0.06%)
REGN : 371.53 (+0.07%)
Progenics Pharmaceuticals Announces Third Quarter 2017 Financial Results and Business Update

-- NDA (New Drug Application) for AZEDRA (iobenguane I 131) Submitted to the U.S. Food and Drug Administration (FDA) on October 31

PGNX : 6.27 (+2.79%)
Progenics Pharmaceuticals Completes Submission of NDA for AZEDRA(R) (iobenguane I 131) in Pheochromocytoma and Paraganglioma

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that it has completed...

PGNX : 6.27 (+2.79%)
Progenics Pharmaceuticals to Participate in November Investor Conferences

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, today announced that management will present...

PGNX : 6.27 (+2.79%)
Progenics Pharmaceuticals Sets Third Quarter 2017 Financial Results Call for November 2

Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that it will host a conference...

PGNX : 6.27 (+2.79%)
Progenics Pharmaceuticals Announces Presentations on AZEDRA(R) (iobenguane I 131) and its Prostate Cancer Programs at the 30th Annual Congress of the European Association of Nuclear Medicine

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that data from several...

PGNX : 6.27 (+2.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic...

See More

Key Turning Points

2nd Resistance Point 6.44
1st Resistance Point 6.35
Last Price 6.27
1st Support Level 6.13
2nd Support Level 6.00

See More

52-Week High 11.72
Fibonacci 61.8% 9.00
Fibonacci 50% 8.16
Fibonacci 38.2% 7.32
Last Price 6.27
52-Week Low 4.60

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.